TETON-1 met its primary endpoint: nebulized Tyvaso improved absolute forced vital capacity (FVC) vs placebo by 130.1 mL from baseline to week 52 (Hodges–Lehmann estimate; 95% CI: 82.2–178.1 mL; p<0.0001). Tyvaso reduced the risk of clinical worsening and showed numerical improvements in time to first acute IPF exacerbation, percent predicted FVC, K-BILD quality-of-life score, and DLCO. Benefits were observed across all subgroups, including background therapy (nintedanib, pirfenidone, or none), smoking status, and supplemental oxygen use. Treatment was well-tolerated with a safety profile consistent with prior Tyvaso studies; no new safety signals were observed. Integrated analyses of TETON-1 and TETON-2 showed statistically significant benefits vs placebo in absolute FVC by 111.8 mL (95% CI: 79.7–144.0; p<0.0001) and most secondary endpoints; overall survival at week 52 trended in favor of Tyvaso but was not statistically significant. United Therapeutics plans to seek FDA priority review of a supplemental New Drug Application (sNDA) by the end of summer 2026 to add IPF to the nebulized Tyvaso label; treprostinil has FDA and EMA orphan designation for IPF. TETON-1 was a 598-patient, multicenter, randomized, double-blind, placebo-controlled phase 3 study in the U.S. and Canada with a 52-week treatment period; full enrollment was reached in January 2025. Additional TETON-1 and integrated data will be presented at the American Thoracic Society Annual Meeting in Orlando in May 2026; TETON-PPF enrollment is ongoing and TETON-OLE open-label extension is available.